The Efficacy and Safty of FMT in Patients With CID
Key facts
- Who runs it
- Peking University Sixth Hospital
- Where
- China7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 80 people enrolled
- Started
- 8 Oct 2023
- Ended
- 24 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- fecal microbiota
- Placebo
- synbiotics
- Record updated
- 27 February 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Diagnosed CID by DSM-5
- 18-60 years old24
- Body Mass Index (BMI) within the range of 18-24 kg/m²
- No other pharmacologic treatment in the last month or at the stable maintenance stage (stable dose for more than two months)
Who cannot take part
- Diagnosis of one or more specific gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis, gastrointestinal tumors, pseudomembranous enteritis, gastrointestinal bleeding, enterocutaneous fistula, etc.)
- Diseases with significant correlations to gut microbiota include Type 2 Diabetes, thyroid disorders, migraines, and autoimmune diseases
- Ex-/intraintestinal organ infection
- Suffering from chronic pain, restless leg syndrome, obstructive sleep apnea, or thyroid disorders
- Central nervous system disorders (e.g., epilepsy, Parkinson's disease, history of traumatic brain injury, cerebrovascular diseases, etc.)
- History of food or antibiotic allergies
- Undergoing or recently received immunosuppressive therapy, or severe immunosuppression (neutrophil count <1500 cells/mm³, lymphocyte count <500 cells/mm³)
- Currently pregnant, planning pregnancy shortly, or breastfeeding
- Abnormal liver or kidney function
- Faecal occult blood test (+)
- Current smokers or alcohol drinkers
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to learn about the efficacy of fecal microbiota transplantation in patients with chronic insomnia disorder. The main question[s] it aims to answer is:
Read full original descriptionShow less
• Effectiveness of the FMT oral capsule route for patients with chronic insomnia Participants in the intervention group will be given FMT by boral capsule pathway, and in the control group, they will be given the same appearance capsules containing starch.
Researchers will compare the sleep status(PSQI and PSG)of the patients in both groups.
The 2 groups in the trial
- FMTTreatment being tested
Investigators have 2 subgroups here, pure Fecal microbiota transplantation-F: Fecal microbiota capsules(0.75g stool/capsule) (60 capsules), within 3 days, another 20 fecal microbiota capsules(0.75g stool/capsule) at week 2. Additionally, they will take placebo B for 45 days from the beginning; Fecal microbiota transplantation+synbiotics-M: Fecal microbiota capsules(0.75g stool/capsule) (60 capsules), within 3 days, another 20 fecal microbiota capsules(0.75g stool/capsule) at week 2. Additionally, they will take synbiotics (Lactobacillus Helveticus Bifidobacterium longum + inulin) (3g/day) for 45 days from the beginning.
Treatment: fecal microbiota and synbiotics
- Non-FMTPlacebo, for comparison
Investigators have 2 subgroups here, synbiotics control-S: PlaceboA capsules (60 capsules), within 3 days, another 20 placeboA capsules(0.75g stool/capsule) at week 2. Additionally, they will take synbiotics (Lactobacillus Helveticas+ Bifidobacterial longum + inulin) (3g/day) for 45 days from the beginning; Double Placebo-P: PlaceboA capsules (60 capsules), within 3 days, another 20 placeboA capsules(0.75g stool/capsule) at week 2. Additionally, they will take placebo B for 45 days from the beginning.
Treatment: Placebo and synbiotics
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Safety and Efficacy of Fecal Microbiota Transplantation in Patients With Chronic Insomnia Disorder
- Publications
- Autonomic modulation following fecal microbiota transplantation in chronic insomnia.Postgraduate medicine, 2026
- Record updated
- 27 February 2026